We provide you with 20 years of free, institutional-grade data for ARQT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ARQT. Explore the full financial landscape of ARQT stock.
| Reported Date | CIK | Ticker | Type |
|---|
Arcutis Biotherapeutics, Inc(NASDAQ:ARQT) 
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atop...
Website: http://www.arcutis.com
Founded: 2016
Full Time Employees: 53
CEO: Todd Franklin Watanabe
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ARQT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.